Top Cannabis Pharmaceuticals Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Cannabis Pharmaceuticals Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Cannabis Pharmaceuticals industry players.

Cannabis Pharmaceuticals Market Competitive Landscape

Several companies in the market are captured in fierce competition as they strive to expand the range of medical conditions that can be treated with cannabis-derived compounds by putting in significant investments in research and development to discover new cannabinoid-based pharmaceuticals. These efforts include the conduction of clinical trials to research and establish the safety and efficacy of cannabis products. In order to speed up market penetration and product development, these companies are employing strategic collaborations. Companies were bringing in a diverse range of offerings to their existing product portfolios by developing various forms of cannabis-based medicines, including transdermal patches, inhalers, oral medications, and more, thus allowing them to cater to a wider range of patient needs and preferences.

Top Player’s Company Profiles

  • Pharmaceutical Group (United Kingdom)
  • GW Pharmaceuticals (United Kingdom)
  • Clever Leaves (Colombia)
  • Cannabis Europa (United Kingdom)
  • Aphria Inc. (Canada)
  • Panaxia Pharmaceuticals (Israel)
  • Aphria Inc. (Canada)
  • Cresco Labs (USA)
  • Canopy Growth Corporation (Canada)
  • Cronos Group Inc. (Canada)
  • Green Thumb Industries Inc. (USA)
  • Charlotte's Web Holdings, Inc. (USA)
  • Harvest Health & Recreation Inc. (USA)
  • TerrAscend Corp. (Canada)
  • Trulieve Cannabis Corp. (USA)
  • Acreage Holdings, Inc. (USA)
  • Curaleaf Holdings, Inc. (USA)
REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Cannabis Pharmaceuticals Market size was valued at USD 3.93 Billion in 2024 and is poised to grow from USD 6.17 Billion in 2025 to USD 228.93 Billion by 2033, growing at a CAGR of 57.1% during the forecast period (2026–2033).

Several companies in the market are captured in fierce competition as they strive to expand the range of medical conditions that can be treated with cannabis-derived compounds by putting in significant investments in research and development to discover new cannabinoid-based pharmaceuticals. These efforts include the conduction of clinical trials to research and establish the safety and efficacy of cannabis products. In order to speed up market penetration and product development, these companies are employing strategic collaborations. Companies were bringing in a diverse range of offerings to their existing product portfolios by developing various forms of cannabis-based medicines, including transdermal patches, inhalers, oral medications, and more, thus allowing them to cater to a wider range of patient needs and preferences. 'Jazz Pharmaceuticals plc (Ireland) ', 'Insys Therapeutics, Inc. (USA) ', 'Corbus Pharmaceuticals Holdings, Inc. (USA) ', 'Botanix Pharmaceuticals Ltd (Australia) ', 'Canopy Growth Corporation (Canada) ', 'Tilray Brands, Inc. (USA) ', 'Aurora Cannabis Inc. (Canada) ', 'Almac Group (UK) ', 'Catalent, Inc. (USA) ', 'Cara Therapeutics, Inc. (USA) ', 'Axim Biotechnologies, Inc. (USA) ', 'MediPharm Labs Corp. (Canada) ', 'ECS Botanics (Australia) ', 'Neurotech International (Australia) ', 'Emyria Limited (Australia)'

A prominent driver in the cannabis pharmaceutical market is the growing rate of legalization of medical cannabis in various countries and states. As more areas accept and permit the use of cannabis for medicinal purposes, it strengthens the market's potential.

Diverse Product Formats: Consumer choice and accessibility of cannabis products is increasing with the introduction of an expanding range of product formats, including edibles, oils, and capsules.

North America, led by countries like the United States and Canada, has been one of the most prominent regions in the global cannabis pharmaceutical market. In recent years, North America has seen a boom in both medical and recreational cannabis legalization, further stimulating market growth. Driven by the increasing acceptance of cannabis as a treatment option and the availability of multiple cannabis-derived pharmaceuticals, the United States, in particular, has seen a tremendous development in the use of cannabis for medicinal purposes. Moreover, North America's rich ecosystem of research and development and the presence of major cannabis pharmaceutical companies greatly contribute to retaining its position in the market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Cannabis Market
Buy Now GET FREE SAMPLE
Medical Cannabis Market
Buy Now GET FREE SAMPLE
Cannabis Tech Market
Buy Now GET FREE SAMPLE
Pharmaceuticals Market
Buy Now GET FREE SAMPLE
Legal Cannabis Market
Buy Now GET FREE SAMPLE
Cannabis Testing Market
Buy Now GET FREE SAMPLE
U.S. Cannabinoids Market
Buy Now GET FREE SAMPLE
North America Legal Cannabis Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Cannabis Pharmaceuticals Market
Cannabis Pharmaceuticals Market

Report ID: SQMIG35I2243

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE